SCHEMBL20738397

SCHEMBL20738397

CNCCCNCCCCNC(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 2/20 0.40
CYP1A2 P05177 1/20 0.40
EPHX1 P07099 1/20 0.39
PAOX Q6QHF9 1/20 0.38
MAPT P10636 1/20 0.37
ALDH1A1 P00352 1/20 0.36
TSHR P16473 1/20 0.36
MEN1 O00255 1/20 0.36
GLA P06280 1/20 0.36
KMT2A Q03164 1/20 0.36
HRH4 Q9H3N8 2/20 0.34
HRH3 Q9Y5N1 2/20 0.34
SIGMAR1 Q99720 1/20 0.33
S1PR2 O95136 5/20 0.32
S1PR4 O95977 5/20 0.32
S1PR1 P21453 5/20 0.32
S1PR3 Q99500 5/20 0.32
S1PR5 Q9H228 1/20 0.32
CA12 O43570 1/20 0.32
CA2 P00918 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12323375 1.00 CYP2C19 (0.40) CYP2C19CYP1A2EPHX1PAOXMAPT
SCHEMBL23739843 1.00 CYP2C19 (0.40) CYP2C19CYP1A2EPHX1PAOXMAPT
SCHEMBL14548641 0.91 CYP2C19 (0.36) CYP2C19CYP1A2EPHX1PAOXMAPT
SCHEMBL12319688 0.90 CYP2C19 (0.48) CYP2C19CYP1A2MAPTALDH1A1TSHR
SCHEMBL11044686 0.90 CYP2C19 (0.48) CYP2C19CYP1A2MAPTALDH1A1TSHR
SCHEMBL8222606 0.90
SCHEMBL11293486 0.90 EPHX1 (0.46) EPHX1PAOXHRH4HRH3SIGMAR1
SCHEMBL22458762 0.87 EPHX1 (0.50) EPHX1PAOXMAPTHRH4HRH3
SCHEMBL18458888 0.87 EPHX1 (0.50) EPHX1PAOXMAPTHRH4HRH3
SCHEMBL21880702 0.87 EPHX1 (0.50) EPHX1PAOXMAPTHRH4HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024064769-A1 INDUCTION OF STEM-LIKE ACTIVATED T CELLS PHIO PHARMACEUTICALS CORP. (US) 2024-03-28 WO disclosed
WO-2023130021-A1 CHEMICALLY MODIFIED OLIGONUCLEOTIDES WITH IMPROVED DELIVERY PROPERTIES PHIO PHARMACEUTICALS CORP. (US) 2023-07-06 WO disclosed
WO-2023015265-A2 CHEMICALLY MODIFIED OLIGONUCLEOTIDES PHIO PHARMACEUTICALS CORP. (US) 2023-02-09 WO disclosed
WO-2023015264-A1 IMMUNOTHERAPY OF CANCER UTILIZING NATURAL KILLER CELLS TREATED WITH CHEMICALLY MODIFIED OLIGONUCLEOTIDES PHIO PHARMACEUTICALS CORP. (US) 2023-02-09 WO disclosed
EP-3188799-B1 METHODS FOR TREATING AGING AND SKIN DISORDERS USING NUCLEIC ACIDS TARGETING TYR OR MMP1 PHIO PHARM CORP (US) 2022-07-06 EP disclosed
EP-3560503-B1 RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS PHIO PHARM CORP (US) 2021-11-17 EP disclosed
EP-3578183-B1 RNA INTERFERENCE IN OCULAR INDICATIONS PHIO PHARM CORP (US) 2021-09-08 EP disclosed
EP-3862005-A1 NUCLEIC ACID MOLECULES TARGETING SUPEROXIDE DISMUTASE 1 (SOD1) Phio Pharmaceuticals Corp. (US) 2021-08-11 EP disclosed
WO-2021138537-A1 CHEMICALLY MODIFIED OLIGONUCLEOTIDES WITH IMPROVED SYSTEMIC DELIVERY PHIO PHARMACEUTICALS CORP. (US) 2021-07-08 WO disclosed
EP-3319614-B1 NUCLEIC ACID MOLECULES TARGETING SUPEROXIDE DISMUTASE 1 (SOD1) PHIO PHARM CORP (US) 2020-12-23 EP disclosed
EP-3137119-B1 METHODS FOR TREATING CANCER USING A NUCLEIC ACID TARGETING MDM2 PHIO PHARM CORP (US) 2020-07-01 EP disclosed
WO-2019032619-A9 CHEMICALLY MODIFIED OLIGONUCLEOTIDES PHIO PHARMACEUTICALS CORP. (US) 2020-02-13 WO disclosed
EP-2550001-B1 RNA INTERFERENCE IN OCULAR INDICATIONS PHIO PHARM CORP (US) 2019-05-22 EP disclosed
EP-2550002-B1 RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS PHIO PHARM CORP (US) 2019-05-08 EP disclosed
WO-2019032619-A1 CHEMICALLY MODIFIED OLIGONUCLEOTIDES PHIO PHARMACEUTICALS CORP. (US) 2019-02-14 WO disclosed